Welcome to our dedicated page for INNOVATIVE EYEWEAR SEC filings (Ticker: LUCYW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innovative Eyewear, Inc. Series A Warrants (LUCYW) SEC filings page centralizes access to the company’s regulatory disclosures related to both its common stock (LUCY) and its exchange‑listed warrants. Innovative Eyewear files reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934, and these documents provide detailed information on its smart eyewear business, capital structure, governance and warrant activity.
Key filings include current reports on Form 8‑K, which disclose material events such as inducement letter agreements with existing warrant holders, the issuance of new warrant series, and changes to at‑the‑market offering programs. For example, recent 8‑K filings describe agreements under which holders exercised existing warrants for cash in exchange for new Series I warrants, outline the terms of placement agent warrants, and specify that both the common stock and warrants are listed on The Nasdaq Stock Market LLC under the symbols LUCY and LUCYW.
Definitive proxy statements on Schedule 14A (DEF 14A) provide insight into governance matters, including director elections, auditor ratification, rights plan amendments and proposals to amend the Articles of Incorporation to change the company’s name to Lucyd, Inc. These proxy materials also explain how shareholders can vote at the annual meeting and identify which securities are entitled to vote.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q, referenced in the proxy materials, contain audited and interim financial statements, risk factors and management’s discussion of the smart eyewear operations that underpin the value of LUCY common stock and LUCYW warrants. Together with Form 4 insider transaction reports and registration statements covering warrant exercises and resale arrangements, these filings allow investors to track equity issuance, warrant terms, and other capital markets activities.
On Stock Titan, each new Innovative Eyewear filing is surfaced shortly after it appears in the SEC’s EDGAR system. AI‑generated summaries help explain the purpose and main points of complex documents, such as warrant inducement agreements, at‑the‑market prospectus supplements, and proxy proposals, so that readers can quickly understand how a filing may relate to LUCY shares or LUCYW warrants without reading every page.
Innovative Eyewear, Inc. (Nasdaq: LUCY / LUCYW) filed an 8-K disclosing a cash-for-warrant inducement completed on 20 June 2025. The company persuaded holders of 746,782 existing warrants (originally issued 14 Apr 2025, strike $2.60) to exercise in full. In exchange, the holders purchased—at $0.125 per warrant—2,240,346 new Series I warrants ("New Warrants") that carry the same $2.60 exercise price, are immediately exercisable and expire 18 months after the related resale registration statement becomes effective.
Gross proceeds total approximately $2.2 million (≈ $1.94 million from warrant exercise plus ≈ $0.28 million from New Warrant purchase). Net proceeds will be lower after:
- Placement agent cash fee: 7.5 % of gross
- Management fee: 1.0 % of gross
- Expenses: $90,950 (accountable, non-accountable and clearing)
Placement agent H.C. Wainwright & Co. also received:
- 56,009 PA Warrants (strike $3.25, 18-month term)
- 73,990 Ordinary-Course PA Warrants (strike $3.25, expire 20 Jun 2030)
The company must file a resale registration statement for the New Warrant shares within 30 days and seek SEC effectiveness within 60 days (90 days if fully reviewed). It agreed to:
- Refrain from issuing or registering additional equity for 30 days
- Avoid variable-rate transactions for one year (limited exception)
Use of proceeds: working capital and general corporate purposes.
Capital structure impact: Immediately adds 746,782 common shares; a further 2,240,346 shares (plus 130,000+ PA-related shares) could enter the float if all new warrants are exercised, creating a sizeable potential dilution relative to the modest cash infusion.